BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion

- BioNTech has expanded its alliance with MediLink, investing $1.8 billion in the partnership.
- The alliance focuses on the development of antibody-drug conjugate (ADC) technology.
- ADCs are a type of targeted therapy that combines antibodies with toxic drugs to selectively kill cancer cells.
- The partnership aims to enhance BioNTech's ADC capabilities, leveraging MediLink's platform.
- This significant investment underscores BioNTech's commitment to advancing ADC technology and its potential in cancer treatment.